Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)‘s stock had its “neutral” rating restated by equities researchers at Chardan Capital in a report issued on Sunday.

Other equities research analysts have also issued research reports about the company. Ladenburg Thalmann Financial Services dropped their price target on Achillion Pharmaceuticals from $9.00 to $6.50 and set a “buy” rating on the stock in a research note on Tuesday, September 12th. Maxim Group set a $7.00 price target on Achillion Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, August 9th. BidaskClub upgraded Achillion Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, July 6th. Zacks Investment Research upgraded Achillion Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, July 18th. Finally, Robert W. Baird lowered Achillion Pharmaceuticals from an “outperform” rating to a “neutral” rating and set a $5.00 price target on the stock. in a research note on Thursday, August 10th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $6.50.

Shares of Achillion Pharmaceuticals (NASDAQ:ACHN) opened at 3.86 on Friday. Achillion Pharmaceuticals has a 52 week low of $3.15 and a 52 week high of $9.19. The stock has a 50 day moving average of $4.48 and a 200-day moving average of $4.20. The stock’s market cap is $527.90 million.

Achillion Pharmaceuticals (NASDAQ:ACHN) last issued its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.16). During the same period in the previous year, the business posted ($0.14) EPS. Equities research analysts predict that Achillion Pharmaceuticals will post ($0.66) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This piece of content was first posted by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/09/20/achillion-pharmaceuticals-inc-achn-given-neutral-rating-at-chardan-capital.html.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Cambridge Investment Research Advisors Inc. boosted its position in Achillion Pharmaceuticals by 3.6% in the second quarter. Cambridge Investment Research Advisors Inc. now owns 23,130 shares of the biopharmaceutical company’s stock valued at $106,000 after buying an additional 800 shares during the last quarter. SG Americas Securities LLC boosted its position in Achillion Pharmaceuticals by 18.6% in the second quarter. SG Americas Securities LLC now owns 26,429 shares of the biopharmaceutical company’s stock valued at $121,000 after buying an additional 4,144 shares during the last quarter. TradeLink Capital LLC purchased a new stake in Achillion Pharmaceuticals in the second quarter valued at approximately $132,000. Dynamic Technology Lab Private Ltd purchased a new stake in Achillion Pharmaceuticals in the first quarter valued at approximately $138,000. Finally, Highbridge Capital Management LLC purchased a new stake in Achillion Pharmaceuticals in the first quarter valued at approximately $149,000. Hedge funds and other institutional investors own 74.11% of the company’s stock.

About Achillion Pharmaceuticals

Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.

Analyst Recommendations for Achillion Pharmaceuticals (NASDAQ:ACHN)

Receive News & Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.